Replies to post #226005 on Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

If P2a was a fail as you state the company wouldn't have spent the money on a P2b not only that the FDA would not have signed off on it.

[Snowy_Owl]

A true dissater! Whatever that is.

What a disssater all around.

[kfcyahoo]

6M$bio,

"Prurisol P2b.. what do we know? Let’s start with it FAILED in P2a."

Then why did they fda approve ph2b?

I said I would not post it again but you convinced me otherwise. Listen (I doubt you will) to the attached link when the fda held the Focused Patient Drug Development conference in Washington D.C back on 3/17/16. which was attended in person by many psoriasis patients(also via phone and internet).

https://collaboration.fda.gov/p10ihzl1hdm/?launcher=false&fcsContent=true&pbMode=normal

Also, please refer to to the link below to my post yesterday comparing ipix(# 3 on my list) to 13 other ph 2 psoriasis trials.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140289370

The history of Brodalumab(administered via injection) still has legs even considering the following (in qoutes) from wikipedia:

"Brodalumab was developed by Amgen, Inc. as AMG 827.

In 2013 it was in two phase III clinical trials for the treatment of moderate to severe psoriasis.[4][5]

In November 2014, Amgen and AstraZeneca reported encouraging results for the compound. The companies stated that the compound met the primary endpoint showing superior skin clearance in a Phase III trial when compared to ustekinumab and a placebo.[6]

However, in May 2015, Amgen announced that it was ending its participation in co-development of the compound because of reports of patients having "events of suicidal ideation and behavior".[7] AstraZeneca will be solely responsible for any future development and marketing of brodalumab in all territories except for certain Asian territories such as Japan, where Kyowa Hakko Kirin has rights to brodalumab and continued as KHK4827.

In September 2015, AstraZeneca announced a partnership with Valeant Pharmaceuticals in which Valeant took over exclusive rights to develop and commercialize brodalumab.[8] In July 2016, the rights to commercialize brodalumab in Europe were sold to LEO Pharma.[9]

In January 2016, a biologics license application (BLA) was submitted to the US FDA.[10] Approval followed in February 2017.[3]"

Note, khk4827(brodalumab) is listed as #2 on my list(second link noted), and after investigating further, and as noted by wikipedia,it comes with a lot of issues.

If Prurisol performs as Dr Bertolino and LE seem to indicate, P will do well.

Listen to the patients urgency/concerns during that fda recorded meeting(first link above).

[Echo20]

6mdb

Note there are many competition medicines in the psoriasis league! Many.

Many of those have long disclosure statements in their commercials.

P has relatively low toxicity and could improve psoriasis treatments.

P could be a winning medicine


Echo20